Drug Profile
AL 37807
Latest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Class Antiglaucomas
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 14 May 2014 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
- 31 Mar 2007 Phase-II clinical trials in Glaucoma in USA (Ophthalmic)